ANI Pharmaceuticals, Inc. (ANIP)
Automate Your Wheel Strategy on ANIP
With Tiblio's Option Bot, you can configure your own wheel strategy including ANIP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ANIP
- Rev/Share 37.6827
- Book/Share 22.0206
- PB 3.8359
- Debt/Equity 0.7329
- CurrentRatio 2.5445
- ROIC 0.0094
- MktCap 1897041451.0
- FreeCF/Share 5.615
- PFCF 17.034
- PE -151.8791
- Debt/Assets 0.2383
- DivYield 0
- ROE -0.0254
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ANIP | H.C. Wainwright | -- | Buy | -- | $84 | July 10, 2025 |
| Initiation | ANIP | Jefferies | -- | Buy | -- | $80 | March 14, 2025 |
| Initiation | ANIP | JP Morgan | -- | Overweight | -- | $85 | March 12, 2025 |
| Initiation | ANIP | Leerink Partners | -- | Outperform | -- | $80 | Dec. 11, 2024 |
| Initiation | ANIP | Piper Sandler | -- | Overweight | -- | $68 | Oct. 11, 2024 |
News
ANIP vs. AMRX: Which Niche Drugmaker Is the Better Pick?
Published: November 28, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI Pharmaceuticals' rare-disease momentum, led by surging Cortrophin Gel sales, sets up a stronger growth profile than its diversified rival.
Read More
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
Published: November 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how ANI Pharmaceuticals (ANIP) and Black Diamond (BDTX) have performed compared to their sector so far this year.
Read More
Here's How ANIP's Rare Disease Portfolio Is Driving Top-line Growth
Published: November 21, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI Pharmaceuticals' rare disease surge, led by Cortrophin Gel, drives major 2025 revenue gains despite softer ophthalmology sales.
Read More
ANI (ANIP) Loses 15% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Published: November 19, 2025 by: Zacks Investment Research
Sentiment: Negative
The heavy selling pressure might have exhausted for ANI (ANIP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Read More
3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP)
Published: November 18, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Read More
ANI (ANIP) Upgraded to Strong Buy: Here's What You Should Know
Published: November 18, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI (ANIP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Read More
ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell?
Published: November 14, 2025 by: Zacks Investment Research
Sentiment: Positive
ANIP's 53% YTD surge fuels strong 2025 financial performance, a raised outlook and powerful momentum in its rare disease portfolio.
Read More
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?
Published: November 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how ANI Pharmaceuticals (ANIP) and Black Diamond (BDTX) have performed compared to their sector so far this year.
Read More
Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock?
Published: November 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
ANI Pharmaceuticals, Inc. (ANIP) Q3 2025 Earnings Call Transcript
Published: November 07, 2025 by: Seeking Alpha
Sentiment: Neutral
ANI Pharmaceuticals, Inc. ( ANIP ) Q3 2025 Earnings Call November 7, 2025 8:30 AM EST Company Participants Nikhil Lalwani - President, CEO & Director Christopher Mutz - Senior Vp & Head of Rare Disease Stephen Carey - Senior VP of Finance & CFO Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Faisal Khurshid - Leerink Partners LLC, Research Division David Amsellem - Piper Sandler & Co., Research Division Daniel Krizay - Guggenheim Securities, LLC, Research Division Gary Nachman - Raymond James & Associates, Inc., Research Division Ekaterina Knyazkova - JPMorgan Chase & Co, Research Division Brandon Folkes …
Read More
Compared to Estimates, ANI (ANIP) Q3 Earnings: A Look at Key Metrics
Published: November 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for ANI (ANIP) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Beat Estimates
Published: November 07, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $1.74 per share. This compares to earnings of $1.34 per share a year ago.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: October 31, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
ANI Pharmaceuticals to Report Q3 Earnings: Is a Beat in the Cards?
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Positive
ANIP's rising Cortrophin Gel sales and new rare disease products, along with generic and other segments, could power another earnings beat this quarter.
Read More
Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes"
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI (ANIP) possesses solid growth attributes, which could help it handily outperform the market.
Read More
Has ANI Pharmaceuticals (ANIP) Outpaced Other Medical Stocks This Year?
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how ANI Pharmaceuticals (ANIP) and Cognition Therapeutics, Inc. (CGTX) have performed compared to their sector so far this year.
Read More
ANI (ANIP) Upgraded to Strong Buy: Here's Why
Published: October 16, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI (ANIP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Read More
Why ANI (ANIP) Could Beat Earnings Estimates Again
Published: October 15, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: October 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Read More
3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP)
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI (ANIP) could produce exceptional returns because of its solid growth attributes.
Read More
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how ANI Pharmaceuticals (ANIP) and Celldex Therapeutics (CLDX) have performed compared to their sector so far this year.
Read More
Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes"
Published: September 24, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI (ANIP) could produce exceptional returns because of its solid growth attributes.
Read More
5 Biotech Stocks Worth Adding to Your Portfolio Now
Published: September 23, 2025 by: Zacks Investment Research
Sentiment: Positive
The volatile biotech industry has done reasonably well so far in 2025 amid the ongoing tariff saga. Most pharma/biotech bigwigs are now investing heavily in manufacturing plants/operations in the United States as the Trump administration threatened of levying heavy tariffs on pharmaceutical imports (upto 250%) in a bid to boost domestic production.
Read More
ANI Pharmaceuticals (ANIP) is a Great Momentum Stock: Should You Buy?
Published: August 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Does ANI Pharmaceuticals (ANIP) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes"
Published: August 22, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Read More
ANI Pharmaceuticals, Inc. (ANIP) Hits Fresh High: Is There Still Room to Run?
Published: August 22, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Read More
ANI (ANIP) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for ANI (ANIP) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
ANI Pharmaceuticals, Inc. (ANIP) Q2 2025 Earnings Call Transcript
Published: August 08, 2025 by: Seeking Alpha
Sentiment: Neutral
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q2 2025 Earnings Conference Call August 8, 2025 8:30 AM ET Company Participants Christopher K. Mutz - Senior VP & Head of Rare Disease Nikhil Lalwani - President, CEO & Director Stephen P.
Read More
Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?
Published: July 14, 2025 by: Zacks Investment Research
Sentiment: Positive
ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
Purified Cortrophin Gel is the only ACTH therapy approved by the FDA for the treatment of acute gout flares Trial to be conducted by Dr. Hyon Choi at Massachusetts General Hospital and will compare the safety and efficacy of two dose levels of Purified Cortrophin Gel for the treatment of acute gout flares PRINCETON, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the initiation of a Phase 4 clinical trial at Massachusetts General Hospital to compare the safety and efficacy of two dose levels (40 USP units and 80 USP …
Read More
About ANI Pharmaceuticals, Inc. (ANIP)
- IPO Date 2000-05-05
- Website https://www.anipharmaceuticals.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Nikhil Lalwani
- Employees 897